

# Taiga Nishihori

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3651083/publications.pdf>

Version: 2024-02-01

144  
papers

3,787  
citations

147801

31  
h-index

168389

53  
g-index

152  
all docs

152  
docs citations

152  
times ranked

4902  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2014, 124, 2596-2606.	1.4	228
2	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3741-3749.	1.6	163
3	Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2621-2633.	1.4	137
4	High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3268-3276.	5.2	134
5	Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1615-1624.	2.0	99
6	Salvage Second Hematopoietic Cell Transplantation in Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 760-766.	2.0	98
7	Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 402-408.e1.	2.0	98
8	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. <i>JAMA Oncology</i> , 2018, 4, 1245.	7.1	97
9	Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1677-1686.	2.0	95
10	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	5.2	89
11	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 3291-3305.	1.4	85
12	A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2012, 97, 1882-1889.	3.5	82
13	Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus on Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1006-1012.	2.0	75
14	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 535-555.	2.4	75
15	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
16	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	5.2	71
17	Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. <i>Cancer</i> , 2017, 123, 3141-3149.	4.1	65
18	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 642-649.	1.2	65

#	ARTICLE	IF	CITATIONS
19	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
20	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	1.6	61
21	Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. <i>Leukemia</i> , 2018, 32, 986-995.	7.2	60
22	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017, 179, 781-789.	2.5	56
23	HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. <i>Blood</i> , 2022, 139, 1452-1468.	1.4	52
24	Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. <i>Journal of Hematology and Oncology</i> , 2010, 3, 36.	17.0	47
25	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1254-1265.	2.4	47
26	Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. <i>Clinical Cancer Research</i> , 2020, 26, 4823-4831.	7.0	47
27	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	7.2	45
28	Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Hematology and Oncology</i> , 2013, 6, 2.	17.0	42
29	Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injuryâ€“Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. <i>JAMA Network Open</i> , 2020, 3, e1918668.	5.9	40
30	Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 507-511.	0.4	37
31	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 802-814.	2.0	37
32	ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1237-1244.	2.0	35
33	Comparative Analysis of Calcineurin Inhibitorâ€“Based Methotrexate and Mycophenolate Mofetilâ€“Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 73-85.	2.0	35
34	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
35	Post-Transplant Outcomes in High-Risk Compared with Nonâ€“High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.	2.0	34
36	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33

#	ARTICLE	IF	CITATIONS
37	IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2017, 102, 948-957.	3.5	33
38	Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 478-485.	2.0	31
39	Dysglycemia Following Glucocorticoid Therapy for Acute Graft-versus-Host Disease Adversely Affects Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 239-248.	2.0	28
40	Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. <i>Immunotherapy</i> , 2016, 8, 435-447.	2.0	28
41	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1648-1659.	5.2	28
42	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	7.2	27
43	Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. <i>Blood Advances</i> , 2021, 5, 975-983.	5.2	27
44	Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. <i>Annals of Transplantation</i> , 2010, 15, 21-9.	0.9	27
45	A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. <i>Blood Advances</i> , 2021, 5, 1154-1163.	5.2	26
46	<i>In vivo</i> IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2018, 103, 531-539.	3.5	25
47	Carpal Tunnel Syndrome Associated with the Use of Aromatase Inhibitors in Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, 362-365.	2.4	24
48	Incidence and Management of Colorectal Cancer in Liver Transplant Recipients. <i>Clinical Colorectal Cancer</i> , 2008, 7, 260-266.	2.3	23
49	Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. <i>Bone Marrow Transplantation</i> , 2015, 50, 1057-1062.	2.4	23
50	Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4086-4090.	5.2	22
51	Bortezomib salvage followed by a phase II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. <i>British Journal of Haematology</i> , 2012, 157, 553-563.	2.5	21
52	Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. <i>Blood Advances</i> , 2018, 2, 1198-1206.	5.2	21
53	Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 940-948.	1.2	20
54	Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. <i>Haematologica</i> , 2011, 96, 1351-1356.	3.5	19

#	ARTICLE	IF	CITATIONS
55	Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 776-780.	2.0	19
56	Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. <i>Haematologica</i> , 2015, 100, 970-977.	3.5	19
57	Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. <i>Bone Marrow Transplantation</i> , 2019, 54, 1354-1360.	2.4	19
58	TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 753-758.	0.4	18
59	Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e35-e39.	0.4	18
60	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 683-688.	2.0	18
61	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
62	Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. <i>Bone Marrow Transplantation</i> , 2017, 52, 1003-1009.	2.4	17
63	Outcomes of rituximab+BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.	4.1	17
64	Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 111.e1-111.e8.	1.2	16
65	Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. <i>International Journal of Hematology</i> , 2011, 93, 206-212.	1.6	15
66	Therapeutic Advances in the Treatment of Primary Plasma Cell Leukemia: A Focus on Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1144-1151.	2.0	15
67	Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft-versus-Host Disease: Phase I Trial Results. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1074-1082.	2.0	14
68	Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation. <i>Expert Review of Vaccines</i> , 2015, 14, 341-350.	4.4	14
69	Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. <i>Leukemia Research</i> , 2018, 67, 1-5.	0.8	14
70	Sleep disruption among cancer patients following autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 307-314.	2.4	14
71	Comparison of outcomes of HCT in blast phase of <i>BCR-ABL1</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757.	5.2	14
72	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. <i>Blood Advances</i> , 2020, 4, 2084-2094.	5.2	14

#	ARTICLE	IF	CITATIONS
73	Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. <i>Blood Advances</i> , 2019, 3, 2525-2536.	5.2	13
74	Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. <i>Cancer Medicine</i> , 2021, 10, 1936-1943.	2.8	13
75	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	2.4	13
76	Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. <i>Blood Advances</i> , 2022, 6, 3767-3778.	5.2	13
77	Three-dimensional conformal radiotherapy for astrocytic tumors involving the eloquent area in children and young adults. <i>Journal of Neuro-Oncology</i> , 2002, 60, 177-183.	2.9	12
78	Phase II Study of CD4+-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1087-1093.	2.0	12
79	A Critical Appraisal of Extracorporeal Photopheresis as a Treatment Modality for Acute and Chronic Graft-Versus-Host Disease. <i>Biomedicines</i> , 2017, 5, 60.	3.2	12
80	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1099-1106.	2.0	12
81	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	5.2	12
82	Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma. <i>Cancer Research</i> , 2020, 80, 5344-5354.	0.9	12
83	ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 256.e1-256.e7.	1.2	12
84	Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2021, 56, 1683-1690.	2.4	12
85	Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation. <i>British Journal of Haematology</i> , 2021, 194, 145-157.	2.5	12
86	Monoclonal Antibodies in Conditioning Regimens for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1288-1300.	2.0	11
87	Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 118-126.	2.3	11
88	Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma. <i>Bone Marrow Transplantation</i> , 2016, 51, 291-294.	2.4	11
89	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.	2.0	11
90	Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. <i>Clinical Cancer Research</i> , 2021, 27, 2712-2722.	7.0	11



#	ARTICLE	IF	CITATIONS
91	Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone Marrow Transplantation, 2014, 49, 11-16.	2.4	10
92	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 480-487.	2.0	10
93	Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 2021, 56, 2897-2903.	2.4	10
94	Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. British Journal of Haematology, 2018, 180, 854-862.	2.5	9
95	Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,. Blood, 2011, 118, 3979-3979.	1.4	9
96	Myeloablative Intravenous Pharmacokinetically Targeted Busulfan Plus Fludarabine As Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 335-340.	0.4	8
97	Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation. Immunotherapy, 2015, 7, 1059-1071.	2.0	8
98	Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies. Archives of Pathology and Laboratory Medicine, 2022, 146, 485-493.	2.5	8
99	Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma. Hematology/ Oncology and Stem Cell Therapy, 2016, 9, 26-29.	0.9	7
100	Severe Action Tremor Related to Interferon-Alpha 2b Therapy for Malignant Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 526.	1.3	6
101	Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia. Leukemia and Lymphoma, 2020, 61, 1678-1687.	1.3	6
102	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2108-2117.	2.4	6
103	Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. Blood Advances, 2022, 6, 3970-3973.	5.2	6
104	Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. Bone Marrow Transplantation, 2015, 50, 1487-1489.	2.4	5
105	Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 7-13.	0.4	5
106	Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review. International Journal of Genomics, 2017, 2017, 1-6.	1.6	5
107	Haploidentical transplantation as a promising therapy for relapsed hemophagocytic lymphohistiocytosis in an older adult patient. Hematology/ Oncology and Stem Cell Therapy, 2018, 11, 96-98.	0.9	5
108	Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. Biology of Blood and Marrow Transplantation, 2018, 24, 400-405.	2.0	5

#	ARTICLE	IF	CITATIONS
109	Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 242.e1-242.e6.	1.2	5
110	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i> -rearranged AML. Blood Advances, 2022, 6, 828-847.	5.2	5
111	A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Advances, 2022, 6, 259-269.	5.2	5
112	Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Advances, 2022, 6, 3991-3995.	5.2	5
113	Immunotherapy strategies for multiple myeloma: the present and the future. Immunotherapy, 2013, 5, 1005-1020.	2.0	4
114	Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic cell transplantation: a single-center experience and a review of the literature. Bone Marrow Transplantation, 2015, 50, 1388-1392.	2.4	4
115	Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e273-e280.	0.4	4
116	Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 768.e1-768.e6.	1.2	4
117	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplantation, 2022, 57, 31-37.	2.4	4
118	Allogeneic hematopoietic cell transplantation for myelofibrosis: A 10-year experience at single institution. American Journal of Hematology, 2010, 85, 904-907.	4.1	3
119	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Polymorphic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation and Cellular Therapy, 2022, 28, 187.e1-187.e10.	1.2	3
120	A Multidisciplinary Approach for Bone Metastases. Journal of Pain and Symptom Management, 2010, 39, 346-347.	1.2	2
121	Hepatobiliary manifestations of acute myeloid leukemia. Leukemia Research, 2011, 35, e81-e83.	0.8	2
122	A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplantation, 2022, 57, 295-298.	2.4	2
123	Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 185.e1-185.e7.	1.2	2
124	Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis. British Journal of Haematology, 2022, 198, 785-789.	2.5	2
125	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 932-937.	2.4	1
126	ELN 2017 Risk Classification Predicts Survival of AML Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, S112.	2.0	1



#	ARTICLE	IF	CITATIONS
127	Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd. Blood, 2011, 118, 323-323.	1.4	1
128	A Phase 2 Study of Bortezomib Plus High-Dose Melphalan (Mel/Vel) Conditioning for Autologous Hematopoietic Cell Transplantation In Multiple Myeloma,. Blood, 2011, 118, 4158-4158.	1.4	1
129	Alternative Dosing of Cyclophosphamide, Bortezomib and Corticosteroids (CyBorD) for Relapsed/Refractory Multiple Myeloma. Blood, 2011, 118, 5142-5142.	1.4	1
130	Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis. Blood, 2011, 118, 1878-1878.	1.4	1
131	Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?. British Journal of Haematology, 2022, 197, 326-338.	2.5	1
132	Multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for high-risk multiple myeloma: Results of the BMT CTN 1302 Trial. Transplantation and Cellular Therapy, 2022, , .	1.2	1
133	Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma. The Cochrane Library, 0, , .	2.8	0
134	Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia. Lancet Oncology, The, 2016, 17, e1.	10.7	0
135	Accelerated fractionated radiation by concomitant boost (AFX-CB) with concurrent cis-platinum (CDDP) for advanced nasopharyngeal carcinoma. Journal of Clinical Oncology, 2006, 24, 5540-5540.	1.6	0
136	Relapsed and Refractory Multiple Myeloma. Emerging Cancer Therapeutics, 2010, 1, 383-402.	0.1	0
137	Allogeneic Hematopoietic Cell Transplantation for Consolidation of VGPR or CR In Myeloma. Blood, 2011, 118, 4581-4581.	1.4	0
138	Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PBA±R) Using a Novel Principle of CD4-Guided Immune Suppression. Blood, 2011, 118, 3022-3022.	1.4	0
139	Comparison of Sirolimus and Mycophenolate Mofetil As Salvage Treatment for Acute Graft-Versus-Host Disease. Blood, 2011, 118, 4548-4548.	1.4	0
140	Clinicohistologic Assessment of Bone Marrow Engraftment In Patients with Hematologic Malignancies Received Double Umbilical Cord Blood Transplantation â€“ A Single Institutional Observation. Blood, 2011, 118, 4578-4578.	1.4	0
141	Impact of Splenomegaly in the Presence of Negative PET FDG Avidity on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Lymphoid Malignancies. Blood, 2015, 126, 5524-5524.	1.4	0
142	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T-Cell Lymphomas As Front-Line Consolidation or in the Relapsed/Refractory Setting: A Meta-Analysis. Blood, 2015, 126, 4493-4493.	1.4	0
143	Hypo-Albuminemia at Day+90 after Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies Independently Predicts for Inferior Overall Survival and Higher Non-Relapse Mortality. Blood, 2015, 126, 4407-4407.	1.4	0
144	Reduced-Intensity or Myeloablative Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: A Side-By-Side Systematic Review/Meta-Analysis. Blood, 2016, 128, 3551-3551.	1.4	0